Subsequently, a multi-omics research strategy consisting of the gut microbiome, metabolomics, and network pharmacology was applied to systematically uncover the hypoglycemic and lipid-reducing pathways, and identify the potential targets and scientific mechanisms of ATM in ameliorating T2DM and related metabolic disorders. Here, ATM is linked to metabolic disease.